The U.S. in-vitro diagnostics market was valued at $32.94 billion in 2022. It is expected to grow slightly to $33.78 billion in 2023 and reach $56.81 billion by 2030, with an annual growth rate of 7.7% during this period.
The U.S. In-vitro Diagnostics Market is a rapidly growing sector within the healthcare industry, driven by advancements in technology and the increasing demand for quick and accurate diagnostic solutions. This market includes a variety of diagnostic tests and tools used outside the human body, such as blood tests, urine tests, and genetic testing, which help in detecting diseases, monitoring treatment progress, and ensuring preventive healthcare. Key factors fueling market growth include an aging population, rising chronic disease prevalence, and growing awareness of the importance of early diagnosis. The market is also benefitting from the shift towards personalized medicine, with more emphasis on precision diagnostics tailored to individual patient needs. Innovations in point-of-care testing, molecular diagnostics, and AI-based solutions are expected to further transform the landscape. However, challenges such as high costs, regulatory hurdles, and reimbursement issues still exist, affecting market expansion. Despite these obstacles, the U.S. In-vitro Diagnostics Market remains a crucial component of the healthcare ecosystem, ensuring better patient outcomes and more efficient healthcare delivery.
Request a Free Sample PDF:
Market Trend:
The U.S. In-vitro Diagnostics Market is seeing a major shift toward personalized medicine and home testing solutions. With more people seeking fast, convenient, and accurate results, diagnostic companies are focusing on developing advanced molecular and point-of-care testing systems. The trend is also being driven by the growing use of artificial intelligence and data analytics in diagnostics, making testing more efficient and precise.
Market Growth:
The U.S. In-vitro Diagnostics Market continues to grow steadily due to the increasing burden of chronic diseases like diabetes, cancer, and cardiovascular conditions. The COVID-19 pandemic also played a big role in boosting the market, with a huge demand for rapid testing kits. The rise in preventive healthcare, early disease detection, and growing awareness among patients about regular health checkups are key reasons why this market is expanding year after year.
List Of Key Companies Profiled:
Abbott (U.S.)
Hoffmann-La Roche AG (Switzerland)
Thermo Fisher Scientific Inc. (U.S.)
Quest Diagnostics Incorporated (U.S.)
Bio Rad Laboratories, Inc. (U.S.)
BD (Becton, Dickinson, and Company) (U.S.)
Agilent Technologies, Inc. (U.S.)
Quidel Corporation (U.S.)
Siemens Healthcare GmbH (Germany)
Market Segmentation:
The U.S. In-vitro Diagnostics Market is segmented by product type, technology, application, and end-user. In terms of product type, the market includes reagents, instruments, and software. Reagents hold the largest share as they are essential in almost all types of testing procedures. Their repeated use in labs and hospitals makes them a driving factor in the U.S. In-vitro Diagnostics Market.
By technology, the U.S. In-vitro Diagnostics Market includes immunoassay, hematology, molecular diagnostics, microbiology, and coagulation. Molecular diagnostics is growing rapidly due to its ability to detect genetic disorders and infectious diseases with high accuracy.
Based on application, the U.S. In-vitro Diagnostics Market covers oncology, infectious diseases, cardiology, nephrology, and autoimmune diseases. Infectious disease testing holds a major share because of continued demand for flu, COVID-19, and other viral infection diagnostics.
End-users of the U.S. In-vitro Diagnostics Market include hospitals, clinical laboratories, academic institutes, and home care settings. Hospitals and clinical labs are the main users due to their volume of patients and diagnostic needs, but home testing kits are quickly rising in popularity, especially for diabetes and pregnancy tests.
Restraining Factors:
Despite its growth, the U.S. In-vitro Diagnostics Market faces a few challenges. High costs of some advanced diagnostic tools and delays in FDA approvals can slow down market expansion. In addition, reimbursement issues and the lack of skilled professionals in certain areas of diagnostic testing are creating hurdles for both manufacturers and healthcare providers.
Regional Analysis:
Since this market focuses solely on the United States, regional analysis within the country shows that large metropolitan areas like New York, California, and Texas lead in diagnostic testing volume. This is largely due to their population density, strong hospital networks, and access to advanced healthcare technologies. Rural areas, while slower in adoption, are catching up thanks to increased government funding and mobile health initiatives aimed at expanding diagnostic access.
Key Industry Developments:
In February 2023, BD (Becton, Dickinson and Company) received Emergency Use Authorization (EUA) from the USFDA for its molecular diagnostic combination test. This test is designed to detect SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV).
In October 2022, Thermo Fisher Scientific Inc. announced its agreement to acquire Binding Site Group, a company known for its specialized diagnostic assays and instruments. This acquisition will strengthen Thermo Fisher’s portfolio in the specialty diagnostics sector.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free)
APAC: +91 744 740 1245